JAZZ - Why There Could Be at Least 1 More Big Acquisition in the Cannabis Industry This Year
There has been a surge of mergers and acquisitions activity in the cannabis industry of late. Aphria (NASDAQ: APHA) and Tilray (NASDAQ: TLRY) are linking up in one of the sector's highest-profile mergers, and other industries are getting in on the action. Jazz Pharmaceuticals (NASDAQ: JAZZ) is acquiring GW Pharmaceuticals (NASDAQ: GWPH) , maker of Epidiolex, a cannabis-based seizure medication, for $7.2 billion, and a subsidiary of British American Tobacco is taking a 19.9% stake in OrganiGram .
But the wheeling and dealing may not be over just yet. With multiple companies in the industry potentially looking to make moves -- plus an interesting note in a proxy statement relating to the Aphria-Tilray merger -- there is plenty of reason investors should expect there to be at least one more major transaction this year.
Image source: Getty Images.
For further details see:
Why There Could Be at Least 1 More Big Acquisition in the Cannabis Industry This Year